Tempus AI: No AI Interruption Detected
Update - Mar. 18, 2025 Tempus AI continues to slow to the lows below $50 now. The stock is tasty once the shake out is over. Originally posted on Feb. 25 Tempus AI, Inc. has declined 50% from highs, now trading near support despite robust above $50, despite good Q4 results and strong organic growth. The AI precision medicine company delivered 33% organic growth with Diagnostics revenue expanding due to higher test ASPs. Concerns over AI replacement have pressured the stock, yet TEM's proprietary data and hospital network provide defensible moats. At 6.5x 2026 sales and strong contract retention, TEM stock appears undervalued; I am ultra Bullish and see current weakness as a buying opportunity. Tempus AI, Inc. ( TEM ) has seen the stock continue to slide over the last few months, leaving Tempus down 50% from the highs. The AI precision medicine company has seen the stock slip back to support in the $50 to $55 range despite ongoing strong results, including a solid Q4 earnings...